

Claude Negrier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3786597/publications.pdf>

Version: 2024-02-01

20
papers

1,799
citations

840776

11
h-index

752698

20
g-index

20
all docs

20
docs citations

20
times ranked

1020
citing authors

#	ARTICLE	IF	CITATIONS
1	Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective single-centre study. <i>Haemophilia</i> , 2022, 28, 301-307.	2.1	2
2	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 Tj ETQq0 0,0 rgBT /Qverlock 10	2.1	7
3	Management of intracranial haemorrhage in a newborn with inherited factor VII deficiency with the use of rFVIIa aliquots. <i>Haemophilia</i> , 2021, 27, e487-e490.	2.1	2
4	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. <i>Blood</i> , 2021, 137, 2231-2242.	1.4	133
5	Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study. <i>Haemophilia</i> , 2021, 27, e347-e356.	2.1	12
6	The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. <i>Haemophilia</i> , 2021, 27, 854-865.	2.1	21
7	Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1079-1086.	3.4	5
8	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. <i>Haemophilia</i> , 2021, 27, 921-931.	2.1	7
9	Identification of new <i>F8</i> deep intronic variations in patients with haemophilia A. <i>Haemophilia</i> , 2020, 26, 847-854.	2.1	9
10	Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors. <i>Hamostaseologie</i> , 2020, 40, 606-620.	1.9	3
11	Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra [®]): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). <i>Haemophilia</i> , 2019, 25, 731-737.	2.1	43
12	BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. <i>Haemophilia</i> , 2019, 25, 1011-1019.	2.1	23
13	Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). <i>Haemophilia</i> , 2019, 25, 373-381.	2.1	29
14	A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated mini-pump system. <i>Haemophilia</i> , 2019, 25, 1020-1027.	2.1	3
15	The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. <i>Haemophilia</i> , 2019, 25, 33-44.	2.1	63
16	Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. <i>Haematologica</i> , 2018, 103, e181-e183.	3.5	78
17	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. <i>New England Journal of Medicine</i> , 2018, 379, 811-822.	27.0	489
18	Emicizumab should be prescribed independent of immune tolerance induction. <i>Blood Advances</i> , 2018, 2, 2783-2786.	5.2	26

#	ARTICLE	IF	CITATIONS
19	Emicizumab Prophylaxis in Hemophilia A with Inhibitors. <i>New England Journal of Medicine</i> , 2017, 377, 809-818.	27.0	794
20	Safety update on the use of recombinant activated factor VII in approved indications. <i>Blood Reviews</i> , 2015, 29, S34-S41.	5.7	50